Tirzepatide – 60mg
Tirzepatide is a dual incretin peptide that simultaneously activates GLP-1 (glucagon-like peptide-1)
and GIP (glucose-dependent insulinotropic polypeptide) receptors. Its dual-agonist mechanism has
attracted attention for research into weight management, glycemic control, and lipid metabolism.
With a unique ability to influence multiple pathways, Tirzepatide is being widely studied as one
of the most promising peptides in modern metabolic research.
Potential Research Benefits
- Explored in obesity and weight reduction studies
- Studied for insulin sensitivity & glycemic control
- Potential role in lipid metabolism research
- Dual action on GLP-1 and GIP receptors
Scientific Background
By targeting both GLP-1 and GIP receptors, Tirzepatide has been shown in early studies to improve
satiety, reduce food intake, and enhance glucose homeostasis. Research indicates it may provide
synergistic benefits over single-agonist peptides, making it particularly effective in experimental
models of obesity and type 2 diabetes. Its dual incretin design makes it a cornerstone compound for
advanced metabolic studies.
Product Details
- Compound: Tirzepatide
- Form: Lyophilized Powder
- Amount: 60mg per vial
- Purity: ≥99%
- Appearance: White to off-white powder
- Research Use Only: Not for human consumption











Reviews
There are no reviews yet.